Introduction
BURGWELL Biomaterials (Zhejiang) Co., Ltd. is a Chinese biomaterials company founded in 2021 and based in Shaoxing, Zhejiang Province. The company focuses on the research, development, production, and sales of environmentally degradable polymers and positions its work around strategic sectors associated with China’s carbon-neutrality and materials-upgrading agenda, including new materials, new energy, and biopharmaceuticals.
BURGWELL’s product and technology portfolio centers on ε-caprolactone monomer, poly(ε-caprolactone) (PCL), and related biodegradable or bioresorbable materials used in medical, industrial, and energy-related applications. Public company information also links the firm to absorbable surgical sutures, orthopedic splints, dental impressions, artificial bones, medical non-wovens, polyurethane resins, coatings, hot-melt adhesives, 3D printing additives, and battery packaging materials, indicating a platform built around specialty polymer chemistry rather than commodity plastics.
The company has also become known for a large-scale industrial project in Shaoxing Binhai New Area: public reports describe a 3,0000-ton-per-year ε-caprolactone and PCL production base with an investment of roughly RMB 1.05 billion, using an independently developed continuous-flow process rather than conventional stirred-tank reactor technology. That project has been presented in local and industry reporting as an important step in moving BURGWELL from laboratory development into pilot and industrial production.
History and Development
BURGWELL was established in 2021 and is headquartered in Shaoxing, Zhejiang. Its early business description emphasizes the development of degradable polymers for emerging industries under a low-carbon policy framework.
A major development milestone came in 2023–2024, when the company was reported to have relocated or settled in Binhai New Area and advanced from laboratory work to pilot-scale production, a transition described in local reporting as being completed in about 14 months. This period is important because it marked the company’s shift from a newly founded materials venture into an industrialization-focused enterprise.
A second milestone was the launch and permitting of its ε-caprolactone / PCL production base. Public reports state that an environmental assessment for a 30,000-ton-per-year project was approved in 2025, with the project divided into phases and construction scheduled through 2026. Industry reporting indicates the plant is intended to include both monomer production and downstream PCL products.
A third development signal was the company’s recognition in Zhejiang’s innovation ecosystem. Government publication in 2025 listed BURGWELL among innovative small and medium-sized enterprises in Zhejiang. Local reporting also described cooperation with ABB China on next-generation automation technology, suggesting a push toward more advanced process control and industrial digitization.
Business Operations and Segments
BURGWELL’s activities can be grouped into three broad segments:
- Biodegradable and bioresorbable materials for healthcare and specialty applications.
- General specialty materials such as polyurethane resins, coatings, inks, hot-melt adhesives, shoe-material additives, and structural adhesives.
- New-energy-related materials, particularly solid-electrolyte packaging materials for lithium batteries and wearable flexible batteries.
This business structure shows the company straddling medical materials, industrial specialty polymers, and new-energy applications. Its public materials suggest a strategy of leveraging core polymer chemistry to serve multiple downstream markets rather than relying on a single end use.
Products and Technologies
BURGWELL’s published product information highlights ε-caprolactone monomer (CL) and poly(ε-caprolactone) (PCL) as core materials. PCL is a biodegradable polyester valued for its biocompatibility, processability, and controlled degradation behavior, which makes it suitable for medical and specialty applications; BURGWELL’s portfolio reflects those characteristics in its product mix.
Notable product and application areas include:
- Absorbable surgical sutures
- Orthopedic splints and correctors
- Radiotherapy plates
- Dental impressions
- Artificial bones and heart valves
- Medical non-woven fabrics
- Micro-injection and related specialty molding uses
Beyond healthcare, BURGWELL lists industrial materials such as:
- Polyurethane resin
- Coatings and inks
- Hot-melt adhesives
- Non-woven fabric adhesives
- Shoe-material intermediates
- Structural adhesives
- Low-temperature 3D-printing additives
- Organic colorants
- Damping materials
The company’s planned large-scale PCL complex is especially notable for its continuous-flow / microchannel process, which public reporting says was developed in-house and is intended to replace traditional batch reactor methods. In practical terms, that suggests a manufacturing emphasis on process intensification, heat transfer efficiency, and tighter control of polymerization conditions, all of which are important for specialty monomer and polyester production.
Applications and End Markets
BURGWELL serves multiple downstream markets, with the strongest public evidence in the following areas:
- Medical and healthcare
- Industrial adhesives and coatings
- Packaging and nonwovens
- New energy
- Consumer and specialty manufacturing
Public reporting in the state media described the company’s products as serving industrial equipment, consumer packaging, and medical and health fields, indicating a diversified application base. The company’s own product listings further show overlap between biomedical uses and general-purpose specialty materials, which is typical of firms built around bio-based or degradable polyester chemistry.
Global Presence and Market Position
Available public information points to BURGWELL as a domestically focused Chinese specialty materials company with international ambitions but no clearly documented global manufacturing footprint in the sources provided. Its market position appears to be that of an emerging niche producer in bio-based and degradable polyester chemistry, rather than a mass-market plastics giant.
The company’s importance lies less in size than in technology orientation. Its reported continuous-flow process, pilot-to-commercial scaling, and linkage to medical and energy applications place it within a broader Chinese industrial trend toward high-value, differentiated materials.
Sustainability and Environmental Initiatives
BURGWELL explicitly frames its business around environmentally degradable polymers and the carbon-neutrality policy environment. That positioning aligns with the broader shift in China’s materials sector toward lower-impact polymers and specialty products that can substitute for conventional plastics in selected applications.
At the same time, the company’s sustainability profile should be interpreted carefully. While biodegradable polymers can reduce persistence in certain use cases, their environmental benefits depend on feedstock, disposal conditions, product design, and end-of-life infrastructure. The available sources do not provide a full life-cycle assessment, so any claim of broad environmental superiority would be unsupported.
The reported use of continuous-flow production may also have efficiency implications, as such systems are often associated with more controlled reactions and potentially improved operational consistency.
Financial Performance and Economic Impact
BURGWELL is a private company, and the sources available here do not provide audited financial statements or revenues. However, its planned industrial project suggests meaningful capital deployment and local economic impact.
Public reporting places the main project investment at roughly RMB 1.05 billion and notes expected downstream effects on the Shaoxing Binhai New Area industrial chain. Industry coverage also reported projected annual sales, profit, and tax contributions once the project reaches operation, although such estimates should be treated as projected figures rather than confirmed results.
From an industrial-policy perspective, the company contributes to Zhejiang’s push for new materials industrialization, local supply-chain development, and the conversion of laboratory technologies into scalable production.
Leadership and Corporate Governance
Publicly available source material in this set does not provide a full board or executive profile. One government-linked workforce record identifies Wu Junyi in association with the company, but the record does not supply enough context here to characterize the leadership structure in detail.
What is clear from the available material is that BURGWELL has operated with a strong project-led governance model, as shown by the rapid progression from founding to pilot production and then to major-capex industrial construction. The company’s reported collaboration with automation providers also suggests a management emphasis on process control and scale-up discipline.
Innovations and Future Outlook
BURGWELL’s most notable innovation claim is its independent continuous-flow technology for ε-caprolactone and PCL production. If successfully scaled, this approach could improve competitiveness by supporting higher process stability, better thermal management, and more flexible capacity expansion than conventional batch methods.
Its future outlook is closely tied to three factors:
- Successful completion and ramp-up of the Shaoxing production base.
- Market adoption of medical-grade and specialty biodegradable polymers.
- The ability to translate process innovation into cost-efficient, reproducible industrial output.
The company also appears positioned to benefit from rising demand in biomedical materials, specialty adhesives, and battery-related packaging materials, although those markets remain competitive and technically demanding.
Summary
BURGWELL Biomaterials (Zhejiang) Co., Ltd. is an emerging Chinese specialty biomaterials company focused on degradable polymers, particularly ε-caprolactone and PCL. Founded in 2021 and based in Shaoxing, it has progressed rapidly from a research-oriented startup toward industrial-scale production, supported by a large project in Binhai New Area and a process strategy built around continuous-flow manufacturing.
Its significance in the plastics industry lies in its role at the intersection of biodegradable materials, medical applications, and next-generation specialty polymers.
References
- •
CPS+ eMarketplace. (n.d.). BURGWELL BIOMATERIALS (ZHEJIANG) CO., LTD.BURGWELL BIOMATERIALS (ZHEJIANG) CO., LTD.. CPS+ eMarketplace. https://www.chinaplasonline.com/eMarketplace/ExhibitorInfo?CompId=1015371Link